Smad3 promotes adverse cardiovascular remodeling and dysfunction in doxorubicin-treated hearts.
Cobb MS, Tao S, Shortt K, Girgis M, Hauptman J, Schriewer J, Chin Z, Dorfman E, Campbell K, Heruth DP, Shohet RV, Dawn B, Konorev EA.
Cobb MS, et al. Among authors: dorfman e.
Am J Physiol Heart Circ Physiol. 2022 Dec 1;323(6):H1091-H1107. doi: 10.1152/ajpheart.00312.2022. Epub 2022 Oct 21.
Am J Physiol Heart Circ Physiol. 2022.
PMID: 36269647
Free PMC article.